TUCSON, Ariz., May 5, 2021 /PRNewswire/ -- Accelerate
Diagnostics, Inc. (Nasdaq: AXDX)
announced today that management will host a conference call on
Thursday, May 6, 2021 at 4:30 p.m. Eastern Time to review 2021 first
quarter financial results.
To listen by phone, dial +1.877.883.0383 and enter Elite Entry
Number: 4747452. International participants may dial
+1.412.902.6506. Please dial in 10–15 minutes prior to the start of
the conference.
This conference call will also be webcast and can be accessed
from the company's website at ir.axdx.com. A replay of the audio
webcast will be available until August 6,
2021.
A replay of the call will be available by telephone at
+1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the
replay code 10154554 until May 27,
2021.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics
company dedicated to providing solutions for the global challenges
of antibiotic resistance and sepsis. The Accelerate
Pheno® system and Accelerate PhenoTest® BC
kit combine several technologies aimed at reducing the time
clinicians must wait to determine the most optimal antibiotic
therapy for deadly infections. The FDA cleared system and kit fully
automate the sample preparation steps to report phenotypic
antibiotic susceptibility results in approximately 7 hours direct
from positive blood cultures. Recent external studies indicate the
solution offers results 1–2 days faster than existing methods,
enabling clinicians to optimize antibiotic selection and dosage
specific to the individual patient days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and
"ACCELERATE PHENOTEST" and diamond shaped logos and marks are
trademarks or registered trademarks of Accelerate Diagnostics,
Inc.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accelerate-diagnostics-to-host-call-to-review-first-quarter-2021-results-301284788.html
SOURCE Accelerate Diagnostics, Inc.